Grace Halsey

Polycystic ovary syndrome and dysmenorrhea were both identified as reproductive disorders that could help stratify CVD risk in women.

Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.

TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.

TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.

More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.

One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.

TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.

TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.

Driven largely by the widespread increase in diabetes and obesity, the rise in hepatic disease disparately affects minority populations and is outpacing available medical care.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.

We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.

The novel potassium-competitive acid blocker is the first new treatment approved for the potentially cancer-producing GI disease in 30 years.

Infants who attended a recommended follow-up clinic visit after being seen in an ED were also slightly more likely to receive medications outside of guideline recommendations.

The comparable immune responses were observed in 50-to 59-year-olds at high risk of RSV-LRTD as well as a wider group at average risk, according to preliminary phase 3 data.

Poverty is both a cause and a consequence of disability, says pediatric rehabilitation physician Dr Amy Houtrow. She explains more about the connections in this short video.

The 100 mg dose prefilled syringes are in particularly short supply and while the shortage of the 50 mg dose is not as severe, supply will be limited this season.

Get a topline look at 8 of the many studies premiered at IDWeek that have outcomes of interest to primary care clinicians.

Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.

The flexibility to self administer a flu vaccine or to administer to another in a non-clinical setting could greatly expand both access and vaccine uptake.

The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.

The Pfizer product is the first vaccine indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

A pivotal phase 3 clinical trial showed Cologuard significantly more likely than FIT to detect cancerous and advanced precancerous lesions.

IDWeek was packed with so much new science it was hard to make choices. Here we topline 10 with outcomes of interest to primary care, ICYMI.

At the Clinical Trials on Alzheimer's Disease Meeting, October 24-28, the biotech company will update research on lecanemab, aducanumab, and an early-stage disease treatment.

In postmenopausal women with HR+ breast cancer who had obesity, recurrence of breast cancer while on aromatase inhibitor therapy was 18%, report investigators.